RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)

Patent metadata

Field	Value
Publication number	US-9850491-B2
Application number	US-201615224822-A
Country	US
Kind code	B2
Filing date	Aug 1, 2016
Priority date	Aug 2, 2010
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTNNB1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules that are capable of mediating or that medium RNA interference (RNAi) against CTNNB1 gene expression.

First claim

What we claim is:

1. An isolated double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of cadherin-associated protein, beta 1 (CTNNB1), wherein
(a) the siNA comprises a sense strand and an antisense strand;
(b) each strand is independently 15 to 30 nucleotides in length; and
(c) at least one strand comprises at least a 15 nucleotide sequence of SEQ ID NO:5.

2. A double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of cadherin-associated protein, beta 1 (CTNNB1), wherein
(a) the siNA comprises a sense strand and an antisense strand;
(b) each strand is independently 15 to 30 nucleotides in length; and
(c) the antisense strand comprises at least 15 nucleotides having sequence complementary to 5′-CUGUUGGAUUGAUUCGAAA-3′ (SEQ ID NO:5).

3. A double-stranded short interfering nucleic acid (siNA) molecule that inhibits the expression of cadherin-associated protein, beta 1 (CTNNB1), wherein
(a) the siNA comprises a sense strand and an antisense strand;
(b) each strand is independently 15 to 30 nucleotides in length; and
(c) the antisense strand comprises at least a 15 nucleotide sequence of 5′-UUUCGAAUCAAUCCAACAG-3′ (SEQ ID NO:4918); and wherein one of more of the nucleotides are optionally chemically modified.

4. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 , wherein at least one nucleotide is a chemically modified nucleotide.

5. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 further comprising at least one non-nucleotide.

6. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 , wherein at least one nucleotide comprises a universal base.

7. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 , having at least one phosphorothioate internucleotide linkage.

8. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 , comprising a cap on the 3′-end, 5′-end or both 3′ and 5′ ends of at least one strand.

9. The double-stranded short interfering nucleic acid (siNA) molecule according to any one of claims 1 - 3 , comprising one or more 3′- overhang nucleotides on one or both strands.

10. The double-stranded short interfering nucleic acid (siNA) molecule of any one of claims 1 - 3 , comprising SEQ ID NOS: 6370 and 6369.

11. The double-stranded short interfering nucleic acid (siNA) molecule of any one of claims 1 - 3 , comprising SEQ ID NOS: 2021 and 2068.

12. A composition comprising the double-stranded short interfering nucleic acid (siNA) according to any one of claims 1 - 3 in a pharmaceutically acceptable carrier or diluent.

13. A composition comprising:
(a) a double-stranded short interfering nucleic acid (siNA) having SEQ ID NOS: 6370 and 6369;
(b) (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;
(c) cholesterol;
(d) DSPC; and
(e) PEG-DMG.

14. A composition comprising:
(a) a double-stranded short interfering nucleic acid (siNA) having SEQ ID NOS: 2021 and 2068;
(b) (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine;
(c) cholesterol;
(d) DSPC; and
(e) PEG-DMG.

15. A method of treating a human subject suffering from a condition which is mediated by the action, or by loss of action, of CTNNB1, which comprises administering to said subject an effective amount of the double-stranded short interfering nucleic acid (siNA) molecule of claim 10 or 11 .

Assignees

• Sirna Therapeutics Inc

Inventors

• Brown Duncan
• Cunningham James J
• Gindy Marian
• Pickering Victoria
• Stanton Matthew G
• Stirdivant Steven M
• Strapps Walter R

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title